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Purpose of the study
To assess patient (pt) reported outcomes in AI266073, a
48-week, prospective, randomized, open-label, multi-
center study.
Methods
Pts on stable antiretroviral therapy (ART) with HIV-1 RNA
<200 c/mL for >3 months were randomized (2:1) to EFV/
FTC/TDF (single tablet regimen) or to remain on their
baseline regimen (SBR) and were stratified by prior PI- or
NNRTI-based therapy. In addition to efficacy/safety, the
following were collected from both study arms: adherence
by visual analog scale, quality of life by SF-36(v2) survey,
a 20-item self-reported HIV Symptoms Index, and the Per-
ceived Ease of the Regimen for Condition questionnaire.
In the EFV/FTC/TDF arm only, a protocol specific single-
item Preference of Medication (POM) questionnaire was
collected.
Summary of results
300 treated pts (EFV/FTC/TDF 203, SBR 97) were evalu-
ated (prior PI/NNRTI 53%/47%); Through 48 weeks,
89% vs. 88% in the EFV/FTC/TDF vs. SBR arms, respec-
tively, maintained HIV-1 RNA <200 c/mL by TLOVR (ITT;
NC = F). Adherence in both arms at baseline and all visits
was > 96%. Baseline SF-36 scores were similar to the gen-
eral non-HIV infected population. There were no marked
changes in adherence and SF-36 scores for either arm dur-
ing the study. HIV Symptoms Index results demonstrated
improvements in the proportion of pts randomized to
EFV/FTC/TDF who experienced diarrhea or loose bowel
movements (prior PI stratum: 52% at baseline; 32% at
week 48 [p = 0.002]); bloating, pain, or gas in the stomach
(p = 0.002); changes in the way their body looked (p =
0.002); and problems having sex (p = 0.032). There was a
transient worsening of dizziness or lightheadedness
symptoms (observed at week 4 only) in pts switched to
EFV/FTC/TDF (p < 0.02), primarily in pts who switched
from a PI-based regimen. Significantly more pts who
received EFV/FTC/TDF considered it an easier regimen to
take than their previous regimen (p < 0.001) at all study
visits. By POM, pts randomized to EFV/FTC/TDF preferred
this treatment over their previous regimen (p < 0.001) at
all post-baseline visits; 85% reported at week 48 that EFV/
FTC/TDF was "much better" than their previous regimen.
Conclusion
Simplification to EFV/FTC/TDF from a variety of ART
maintained high levels of virologic suppression, adher-
ence and quality of life through 48 weeks. Pts switched to
EFV/FTC/TDF reported improvements in many HIV-
related symptoms, found the new regimen easier to follow
and preferred EFV/FTC/TDF over their previous ART regi-
men.
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